Literature DB >> 30578253

Arterial thromboembolic events preceding the diagnosis of cancer in older persons.

Babak B Navi1,2,3, Anne S Reiner1, Hooman Kamel1,2, Costantino Iadecola1,2, Peter M Okin4, Scott T Tagawa5, Katherine S Panageas6, Lisa M DeAngelis1,2,3.   

Abstract

Cancer patients face an increased risk of arterial thromboembolism; however, it is uncertain when this excess risk begins. This study evaluated the risk of arterial thromboembolism before cancer diagnosis. Using the population-based Surveillance Epidemiology and End Results-Medicare linked dataset, we identified 374 331 patients ≥67 years of age with a new primary diagnosis of breast, lung, prostate, colorectal, bladder, uterine, pancreatic, gastric cancer, or non-Hodgkin lymphoma from 2005 through 2013. Cancer patients were individually matched by demographics and comorbidities to Medicare beneficiaries without cancer, who served as controls. Validated diagnosis codes were used to identify arterial thromboembolic events, defined as a composite of myocardial infarction or ischemic stroke. The Mantel-Haenszel estimator was used to compare risks of arterial thromboembolic events between cancer and noncancer groups during 30-day periods in the 360 days before date of cancer diagnosis. From 360 to 151 days before cancer diagnosis, the 30-day interval risks of arterial thromboembolic events were similar between cancer patients and matched controls. From 150 to 1 day before cancer diagnosis, the interval 30-day risks of arterial thromboembolic events were higher in cancer patients vs matched controls, progressively increasing as the cancer diagnosis date approached and peaking during the 30 days immediately before cancer diagnosis, when 2313 (0.62%) cancer patients were diagnosed with an arterial thromboembolic event vs 413 (0.11%) controls (odds ratio, 5.63; 95% confidence interval, 5.07-6.25). In conclusion, the risk of arterial thromboembolic events begins to increase 150 days before the date of cancer diagnosis in older persons and peaks in the 30 days before.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2018        PMID: 30578253      PMCID: PMC6384185          DOI: 10.1182/blood-2018-06-860874

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  Incident cancer in a cohort of 3,247 cancer diagnosis free ischemic stroke patients.

Authors:  Adnan I Qureshi; Ahmed A Malik; Omar Saeed; Malik M Adil; Gustavo J Rodriguez; M Fareed K Suri
Journal:  Cerebrovasc Dis       Date:  2015-04-08       Impact factor: 2.762

2.  Report of the Committee on Hodgkin's Disease Staging Classification.

Authors:  P P Carbone; H S Kaplan; K Musshoff; D W Smithers; M Tubiana
Journal:  Cancer Res       Date:  1971-11       Impact factor: 12.701

3.  Cancer and Clot: Between a Rock and a Hard Place.

Authors:  Edward T H Yeh; Hui-Ming Chang
Journal:  J Am Coll Cardiol       Date:  2017-08-22       Impact factor: 24.094

Review 4.  Coagulation and cancer: biological and clinical aspects.

Authors:  A Falanga; M Marchetti; A Vignoli
Journal:  J Thromb Haemost       Date:  2013-02       Impact factor: 5.824

5.  Risk of haemorrhagic and ischaemic stroke in patients with cancer: a nationwide follow-up study from Sweden.

Authors:  Bengt Zöller; Jianguang Ji; Jan Sundquist; Kristina Sundquist
Journal:  Eur J Cancer       Date:  2012-01-30       Impact factor: 9.162

6.  Population trends in the incidence and outcomes of acute myocardial infarction.

Authors:  Robert W Yeh; Stephen Sidney; Malini Chandra; Michael Sorel; Joseph V Selby; Alan S Go
Journal:  N Engl J Med       Date:  2010-06-10       Impact factor: 91.245

7.  Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden.

Authors:  Bengt Zöller; Jianguang Ji; Jan Sundquist; Kristina Sundquist
Journal:  Eur J Cancer       Date:  2011-10-22       Impact factor: 9.162

8.  Association between incident cancer and subsequent stroke.

Authors:  Babak B Navi; Anne S Reiner; Hooman Kamel; Costantino Iadecola; Mitchell S V Elkind; Katherine S Panageas; Lisa M DeAngelis
Journal:  Ann Neurol       Date:  2015-01-07       Impact factor: 10.422

9.  First-ever stroke as initial presentation of systemic cancer.

Authors:  Fabio Silvio Taccone; Sandrine M Jeangette; Serge A Blecic
Journal:  J Stroke Cerebrovasc Dis       Date:  2008 Jul-Aug       Impact factor: 2.136

10.  Validating administrative data in stroke research.

Authors:  David L Tirschwell; W T Longstreth
Journal:  Stroke       Date:  2002-10       Impact factor: 7.914

View more
  35 in total

Review 1.  Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin.

Authors:  Katsue Suzuki-Inoue
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Cancer-Related Ischemic Stroke Has a Distinct Blood mRNA Expression Profile.

Authors:  Babak B Navi; Ryna Mathias; Carla P Sherman; Julia Wolfe; Hooman Kamel; Scott T Tagawa; Ashish Saxena; Allyson J Ocean; Costantino Iadecola; Lisa M DeAngelis; Mitchell S V Elkind; Heather Hull; Glen C Jickling; Frank R Sharp; Bradley P Ander; Boryana Stamova
Journal:  Stroke       Date:  2019-09-12       Impact factor: 7.914

3.  Prediction and Prevention of Cancer-Associated Thromboembolism.

Authors:  Alok A Khorana; Maria T DeSancho; Howard Liebman; Rachel Rosovsky; Jean M Connors; Jeffrey Zwicker
Journal:  Oncologist       Date:  2020-12-04

Review 4.  Common Vascular Toxicities of Cancer Therapies.

Authors:  Joerg Herrmann
Journal:  Cardiol Clin       Date:  2019-08-26       Impact factor: 2.213

5.  Increased risk for cancer after stroke at a young age: etiological relevance or incidental finding?

Authors:  Christian Tanislav; Charles Christian Adarkwah; Louis Jakob; Karel Kostev
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-10       Impact factor: 4.553

6.  Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.

Authors:  Federico Nichetti; Francesca Ligorio; Emma Zattarin; Diego Signorelli; Arsela Prelaj; Claudia Proto; Giulia Galli; Antonio Marra; Giulia Apollonio; Luca Porcu; Filippo de Braud; Giuseppe Lo Russo; Roberto Ferrara; Marina Chiara Garassino
Journal:  Cancers (Basel)       Date:  2019-12-25       Impact factor: 6.639

Review 7.  Cancer and Embolic Stroke of Undetermined Source.

Authors:  Babak B Navi; Scott E Kasner; Mitchell S V Elkind; Mary Cushman; Oh Young Bang; Lisa M DeAngelis
Journal:  Stroke       Date:  2021-01-28       Impact factor: 7.914

8.  Driver Genes Associated With the Incidence of Venous Thromboembolism in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Authors:  Xiaohan Qian; Mengjiao Fu; Jing Zheng; Jianya Zhou; Jianying Zhou
Journal:  Front Oncol       Date:  2021-04-29       Impact factor: 6.244

Review 9.  Paraneoplastic Thromboembolism and Thrombophilia: Significance in Visceral Medicine.

Authors:  Christian Pfrepper
Journal:  Visc Med       Date:  2020-07-15

Review 10.  Vascular toxic effects of cancer therapies.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-26       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.